TransMedics (TMDX) Q3 2026 Earnings Call Transcript
TransMedics (TMDX) reported Q3 2026 revenue of $203M, up 41% YoY. Transplant product revenue grew 29% YoY to $113M, while service revenue increased 44% YoY to $79M. The company expects growth to accelerate due to ongoing initiatives. Cash reserves totaled $493M. TransMedics advanced clinical programs for heart and lung transplants, with FDA approvals for key studies. European expansion and kidney transplant developments are also underway.
How this was made

The 30-second read
Why it matters
Earnings beat and cash buildup support near‑term upside, but upcoming clinical trial outcomes remain a risk.
Market read
First earnings report of the quarter; provides fresh data for traders targeting niche biotech stocks.
What to watch
Future cash burn from upcoming clinical programs and European expansion could pressure balance sheet.
Background
TransMedics provides normothermic organ perfusion systems for transplant logistics.
Ticker impact
Q3 2026 earnings release showing $203M revenue, 41% YoY growth and cash balance of $493M.
likely upside as investors price in higher revenue growth and cash strength
Revenue beat expectations and cash buildup typically drive short-term buying pressure for micro‑cap stocks.
Market effects
Highlights growth potential in organ‑preservation market, may boost related biotech and medical device peers.
U.S. biotech sector sees a positive data point; European expansion noted but limited immediate effect.
Limited to niche transplant logistics space; no broad market impact.
Counterpoint
Micro‑cap valuation may already price in growth; any miss on upcoming FDA approvals could reverse gains.
Key entities
- CompanyTransMedics
Medical device company focused on organ preservation.



